Joseph Stringer
Stock Analyst at Needham
(2.32)
# 2,444
Out of 4,842 analysts
319
Total ratings
38.73%
Success rate
-1.25%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Stringer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CDTX Cidara Therapeutics | Reiterates: Buy | $35 | $22.04 | +58.80% | 11 | May 23, 2025 | |
| VIR Vir Biotechnology | Reiterates: Buy | $14 | $5.19 | +169.75% | 18 | May 22, 2025 | |
| GILD Gilead Sciences | Reiterates: Hold | n/a | $111.11 | - | 6 | May 21, 2025 | |
| INZY Inozyme Pharma | Downgrades: Hold | $12 | $3.95 | +203.80% | 20 | May 16, 2025 | |
| ANNX Annexon | Maintains: Buy | $16 → $11 | $2.18 | +404.59% | 19 | May 13, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $40 → $29 | $17.41 | +66.57% | 20 | May 7, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $66 → $72 | $61.88 | +16.35% | 24 | May 7, 2025 | |
| VRTX Vertex Pharmaceuticals | Reiterates: Hold | n/a | $447.09 | - | 6 | May 6, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $60 → $55 | $33.46 | +64.38% | 21 | Apr 30, 2025 | |
| PHAT Phathom Pharmaceuticals | Reiterates: Buy | $28 | $4.31 | +549.65% | 51 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $60 | $31.70 | +89.27% | 17 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $22 | $9.73 | +126.10% | 22 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $320 | $292.90 | +9.25% | 21 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $90 | $32.80 | +174.39% | 17 | Apr 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $0.66 | - | 13 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $10 | $1.37 | +629.93% | 17 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $26.93 | - | 8 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $37 | $22.29 | +65.99% | 6 | Jan 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $18 | $9.27 | +94.17% | 2 | Aug 24, 2021 |
Cidara Therapeutics
May 23, 2025
Reiterates: Buy
Price Target: $35
Current: $22.04
Upside: +58.80%
Vir Biotechnology
May 22, 2025
Reiterates: Buy
Price Target: $14
Current: $5.19
Upside: +169.75%
Gilead Sciences
May 21, 2025
Reiterates: Hold
Price Target: n/a
Current: $111.11
Upside: -
Inozyme Pharma
May 16, 2025
Downgrades: Hold
Price Target: $12
Current: $3.95
Upside: +203.80%
Annexon
May 13, 2025
Maintains: Buy
Price Target: $16 → $11
Current: $2.18
Upside: +404.59%
Apellis Pharmaceuticals
May 7, 2025
Maintains: Buy
Price Target: $40 → $29
Current: $17.41
Upside: +66.57%
Rhythm Pharmaceuticals
May 7, 2025
Maintains: Buy
Price Target: $66 → $72
Current: $61.88
Upside: +16.35%
Vertex Pharmaceuticals
May 6, 2025
Reiterates: Hold
Price Target: n/a
Current: $447.09
Upside: -
Ionis Pharmaceuticals
Apr 30, 2025
Maintains: Buy
Price Target: $60 → $55
Current: $33.46
Upside: +64.38%
Phathom Pharmaceuticals
Apr 21, 2025
Reiterates: Buy
Price Target: $28
Current: $4.31
Upside: +549.65%
Apr 9, 2025
Reiterates: Buy
Price Target: $60
Current: $31.70
Upside: +89.27%
Apr 9, 2025
Reiterates: Buy
Price Target: $22
Current: $9.73
Upside: +126.10%
Apr 9, 2025
Reiterates: Buy
Price Target: $320
Current: $292.90
Upside: +9.25%
Apr 8, 2025
Reiterates: Buy
Price Target: $90
Current: $32.80
Upside: +174.39%
Mar 7, 2025
Reiterates: Hold
Price Target: n/a
Current: $0.66
Upside: -
Mar 4, 2025
Downgrades: Hold
Price Target: $10
Current: $1.37
Upside: +629.93%
Nov 8, 2024
Reiterates: Hold
Price Target: n/a
Current: $26.93
Upside: -
Jan 24, 2024
Upgrades: Buy
Price Target: $37
Current: $22.29
Upside: +65.99%
Aug 24, 2021
Maintains: Buy
Price Target: $32 → $18
Current: $9.27
Upside: +94.17%